Novartis AG – Consensus Indicates Potential 20.2% Upside
Novartis AG with ticker code (NVS) now have 4 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 105 and 97 with a mean TP of 102. With the stocks previous close at 84.86 this indicates there is a potential upside of 20.2%. There is a 50 day moving average of 85.51 and the 200 day MA is 85.85. The company has a market capitalisation of $186,242m. Find out more information at: https:||www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets="NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $223,859m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
Novartis AG – Consensus Indicates Potential 20.2% Upside
Novartis AG with ticker code (NVS) now have 4 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 105 and 97 with a mean TP of 102. With the stocks previous close at 84.86 this indicates there is a potential upside of 20.2%. There is a 50 day moving average of 85.51 and the 200 day MA is 85.85. The company has a market capitalisation of $186,242m. Find out more information at: https:||www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets="NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $223,859m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.